Key result
Antihypertensive therapy achieves 1-year target blood pressure control in ~63% of post-renal transplant patients.
Why the study?
Effective blood pressure control in post renal transplant patients is important for graft function and cardiovascular risk reduction, but data on antihypertensive use and BP control trends in this population are limited.
Observational (n=56)
No
Answers are grounded in this paper and cite their sources.
Target BP control reached in 62.5% of young post-transplant patients at 1 year with no MACE; leaves open generalizability beyond this eastern Indian cohort.
Introduction: The etiology of hypertension in post renal transplant patients is multifold and effective control of blood pressure (BP) contributes towards proper graft functioning and reduces risk of cardiovascular diseases. This prospective observational study was undertaken to evaluate the prevalence of antihypertensive drug use, the prescribing pattern and trends of blood pressure control in a cohort of post renal transplant patients from eastern India. Materials and Methods: Patients who had undergone renal transplant in this public hospital were enrolled as per eligibility criteria. All enrolled patients were on antihypertensive from at least 3months prior to transplant and were followed upto one year post-transplant. Antihypertensive drug (AHD) and immunosuppressant intake, BP recordings and occurrence of major adverse cardiac events (MACE), if any were noted at each visit. Results: 56 patients were enrolled with a mean age of 33.04 ± 9.96 years, 87.5% were male. 75% were hypertensive at discharge (2-3 weeks post-transplant). Percentage of patients on AHD at 3, 6, 9 and 12 months post-transplant were 83.9%, 82.1%, 75% and 71.4% respectively. Amlodipine was the most common prescribed AHD. Target BP control (≤130/80 mm of Hg) was achieved in 62.5% patients at 1year post-transplant. There were no major adverse cardiac events (MACE) during the study period. Conclusion: In our study comprising of a relatively young cohort of transplant patients from India, hypertension control was well achieved in majority of the subjects and no MACE were noted. Amlodipine was the most commonly used AHD either as monotherapy or in combination with beta-blocker. Long term follow up of this cohort shall provide further insights into the trends of such control.
No takes yet. Share an insight, caveat, or question.
Choudhury et al. (2023) conducted an observational in Post-renal transplant hypertension (n=56). Antihypertensive drug therapy was evaluated on Target blood pressure control (≤130/80 mm of Hg) at 1 year post-transplant. Among post-renal transplant patients, antihypertensive drug therapy achieved target blood pressure control (≤130/80 mm Hg) in 62.5% at 1 year, with no major adverse cardiac events observed.
Synapse has enriched 10 related papers. Consider them for comparative context: